Tiziana Life Sciences Secures ALS Trial Funding

Tiziana Life Sciences (TLSA) has released an update.

Tiziana Life Sciences has secured funding from the ALS Association to conduct a 20-patient clinical trial for its innovative intranasal foralumab, a potential therapy aimed at treating ALS. This trial will explore the drug’s safety and early-stage efficacy, with hopes of slowing disease progression in ALS patients. The company’s unique approach aligns with the ALS Association’s mission to find new treatments for this devastating disease.

For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.